Inicio › Cáncer de próstata › Nebraska
Ensayos clínicos de Cáncer de próstata en Nebraska
27 estudios sobre Cáncer de próstata buscan participantes en Nebraska.
Ciudades en Nebraska
Texto oficial del estudio (inglés)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Alegent Health Immanuel Medical Center, Omaha
- y 2 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 oct 2026 · NCT05334069Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT03866382Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Urology Cancer Center, PC, Omaha
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 25 sept 2026 · NCT06800313A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026), Omaha
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06136650Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Nebraska Cancer Specialists, Omaha
ReclutandoFase 2/3
Edades de 18 a 100 · Hombres · Actualizado el 22 sept 2026 · NCT06780670Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Nebraska Cancer Specialists, Omaha
ReclutandoFase 3
Edades de 18 a 100 · Hombres · Actualizado el 22 sept 2026 · NCT06855277PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
- University of Nebraska Medical Center, Omaha
ReclutandoFase 2
Edades de 30 en adelante · Hombres · Actualizado el 21 sept 2026 · NCT07234981A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
- XCancer, Omaha
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 15 sept 2026 · NCT07581184Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- XCancer Omaha LLC, Omaha
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 11 sept 2026 · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 10 sept 2026 · NCT05946213Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
- Research Site, Omaha
ReclutandoFase 1/2
Edades de 18 a 99 · Hombres · Actualizado el 27 ago 2026 · NCT07590934AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Omaha
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 26 ago 2026 · NCT07611110Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- XCancer Omaha, Omaha
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 24 ago 2026 · NCT07745361A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- Nebraska Cancer Specialists, Omaha
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 20 ago 2026 · NCT06785636Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- CHI Health Good Samaritan, Kearney
- Alegent Health Bergan Mercy Medical Center, Omaha
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 19 ago 2026 · NCT04423211Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
- University of Nebraska Medical Center, Omaha
ReclutandoFase 2
Edades de 30 en adelante · Hombres · Actualizado el 19 ago 2026 · NCT07237269Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Alegent Health Immanuel Medical Center, Omaha
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 14 jul 2026 · NCT06592924Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- y 3 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 19 a 110 · Todos los sexos · Actualizado el 29 jun 2026 · NCT02012699Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 jun 2026 · NCT05283330Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- Urology Cancer Center PC, Omaha
- Nebraska Cancer Specialists, Omaha
ReclutandoFase 4
Edades de 18 a 100 · Hombres · Actualizado el 4 jun 2026 · NCT05803941Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
- XCancer Omaha / Urology Cancer Center, Omaha
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 14 may 2026 · NCT05413850A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Research Site, Omaha
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 12 may 2026 · NCT06879041Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- CHI Health Good Samaritan, Kearney
- Saint Elizabeth Regional Medical Center, Lincoln
- Alegent Health Immanuel Medical Center, Omaha
- y 4 más
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 29 ene 2026 · NCT05806515Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 22 ene 2026 · NCT06470243High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
- University of Nebraska Medical Center, Omaha
Reclutando
Edades de 19 en adelante · Hombres · Actualizado el 5 nov 2025 · NCT05754580SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Methodist Hospital, Omaha
- Nebraska Medicine-Village Pointe, Omaha
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 11 sept 2025 · NCT03678025De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.